Quantum-Si incorporated (NASDAQ:QSI) Q1 2024 Earnings Call Transcript

Now, flipping more to the question of sort of, what is the future? I think that software launch, Kyle, the way I would think about it is there is the core analysis software, right? There’s this — as we talked about, there’s a kinetic model and a kinetic database that underpins sort of the general detection and calling of amino acids and alignment of peptides and then ultimately protein identification, if that’s the type of work you’re doing. So, some of these are going to just be improvements we make to keep making those databases more and more accurate, more and more capable, seeing real world sequencing data as a very powerful sort of source of data to be able to fine tune those, but then other aspects are more about purpose built tools.

And I think that’s maybe where the analogy starts to align a little bit closer with some of the analogs you’re giving from the DNA world, dragon or a base space. I think you’ll see us sort of think about the problem in a similar way and that there will be core tools that exist that get used on every run and we’ll seek to continue to improve those tools and make them more accurate and make them able to detect events we haven’t been able to sort of detect before. So I think you’ll also see us think about sort of customized workflows that maybe help do a very specific type of analysis to customers looking to do in a very purpose built way and perhaps be very tuned and tailored for that rather than using the more generic or general software tool.

So I think you’ll see us do a little bit of both. It’s a tremendous opportunity to expand the technology capability and application space and improve the customer’s ability to really apply the tech and it can be done on its own cycle, sort of almost independent of the cycles we are operating here to make new sequencing kits like the version 3 kit.

Kyle Mikson: Okay, that was great Jeff, thanks so much, appreciate it.

Jeff Hawkins: You’re welcome.

Operator: This concludes our question and answer period. I would now like to turn it back over to Jeff Hawkins for closing remarks.

Jeff Hawkins: Thank you everyone for attending today. We believe the progress we’ve made during the first quarter was outstanding. We are excited to be executing on our full commercial launch and we remain on track for our version 3 sequencing kit delivery by the end of Q3 2024. We look forward to providing an update on our next call. Thank you.

Operator: Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.